Work with thought leaders and academic experts from University of Sydney

Dr. Anna Young-Ferris is a sustainability and climate change accounting specialist bringing two decades of academic (research and lecturing) and corporate experience. She worked as a climate change and sustainability professional at Ernst & Young and joined academia in 2010 to pursue her research in the field and was awarded her PhD in Responsible Investment in 2014. Her award-winning PhD study examined the integration of environmental, social and corporate governance (ESG) accounting information in mainstream investment decisions, and she continues to focus and publish her research in the fields of responsible investment, corporate sustainability, and responsible management education. Anna has presented her research at numerous international settings including Harvard University, the London School of Economics and HEC Paris.

* Joint PhD in Engineering and Medical Science with a strong technical background in biochemical engineering, manufacturing process development, analytical test development, molecular biology, and biochemistry. * Over 20 years combined industry experience in a scientific leadership role as a VP/ Senior Director/ Global Director/Head in Research and Development in both small biotech and large biopharma environments. * Broad experience in different aspects of vaccine and therapeutic development including mRNA-LNP, subunit and live viral vaccines, mAbs, animal cell culture, antibody technology, diagnostics, recombinant protein expression and purification, molecular biology, Piggybac transposon technology, baculovirus-insect cell culture, bacterial expression, virology, bioreactor operation and scale-up, assay development, product formulation and stability, bioinformatics, and proteomics. * Strong understanding of CMC regulatory requirements for vaccines and therapeutics and authored numerous  strategy documents (manufacturing, analytical, impurities, troubleshooting), journal publications, risk assessments for different CMC elements, QBD approaches, comparability reports, technical documents, prepared entire CMC DS and DP sections for regulatory submissions (IND, FDA, CTD) as well as IB contributions and briefing packages. * Considerable experience in technology transfer and outsourcing of material manufacture by CDMOs (live virus, mRNA, LNP, plasmid, recombinant protein, antibodies, virus, diagnostic kit manufacture), process validation, and corresponding analytical test development and QC. * Five years as a university academic with collaborators in cancer research, infectious diseases, parasitology, and engineering. Developed DNA-protein expression vectors using transformed cells and licensed to Life Technologies